Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934541 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT03934541 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT03934541, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
Conditions Studied
Interventions
- BIOLOGICAL MPER-656 Liposome Vaccine
- BIOLOGICAL Placebo for MPER-656 Liposome Vaccine
Study Locations (6)
Massachusetts
- Brigham and Women's Hospital Vaccine CRS (BWH VCRS) - Boston
- Fenway Health (FH) CRS - Boston
New York
- Columbia P&S CRS - New York
- New York Blood Center CRS - New York
Alabama
- Alabama CRS - Birmingham
Washington
- Seattle Vaccine and Prevention CRS - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2021-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03934541
The ClinicalTrials.gov registry entry for NCT03934541 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which MPER-656 Liposome Vaccine is the first listed.
NCT03934541 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT03934541 about?
NCT03934541 is a clinical study titled "Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants". The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
What is the current status of trial NCT03934541?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-08-26. Estimated completion is 2021-05-26.
What conditions does trial NCT03934541 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT03934541?
The interventions under investigation include: MPER-656 Liposome Vaccine (BIOLOGICAL), Placebo for MPER-656 Liposome Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03934541?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03934541 being conducted?
This trial has 6 study locations across Alabama, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.